These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17542057)

  • 1. Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.
    Wang LR; Liu J; Huang MZ; Xu N
    J Zhejiang Univ Sci B; 2007 May; 8(5):307-13. PubMed ID: 17542057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
    Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E
    Cancer Chemother Pharmacol; 2010 May; 65(6):1197-202. PubMed ID: 20140616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
    Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
    Soo RA; Wang LZ; Tham LS; Yong WP; Boyer M; Lim HL; Lee HS; Millward M; Liang S; Beale P; Lee SC; Goh BC
    Ann Oncol; 2006 Jul; 17(7):1128-33. PubMed ID: 16670205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.
    Pereira JR; Fein L; Del Giglio A; Blajman CR; Richardet E; Schwartsmann G; Orlando M; Hall BJ; West TM; van Kooten M
    Lung Cancer; 2007 Oct; 58(1):80-7. PubMed ID: 17588704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
    Tempero M; Plunkett W; Ruiz Van Haperen V; Hainsworth J; Hochster H; Lenzi R; Abbruzzese J
    J Clin Oncol; 2003 Sep; 21(18):3402-8. PubMed ID: 12885837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials.
    Qiu MT; Ding XX; Hu JW; Tian HY; Yin R; Xu L
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):861-73. PubMed ID: 23053260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
    Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
    Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.
    Wang LR; Huang MZ; Xu N; Shentu JZ; Liu J; Cai J
    J Zhejiang Univ Sci B; 2005 May; 6(5):446-50. PubMed ID: 15822162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
    Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
    Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile].
    Wang LR; Zhang GB; Huang MZ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 36(4):391-5. PubMed ID: 17717833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
    Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
    Ceribelli A; Gridelli C; De Marinis F; Fabi A; Gamucci T; Cortesi E; Barduagni M; Antimi M; Maione P; Migliorino MR; Giannarelli D; Cognetti F
    Cancer; 2003 Jul; 98(2):337-43. PubMed ID: 12872354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
    Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
    Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
    J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
    Alvarez RD; Mannel R; García AA; Gallion HH; Lucci J; Kilgore LC; Numnum TM; Zou SX; Orlando M; Tai DF
    Gynecol Oncol; 2009 Dec; 115(3):389-95. PubMed ID: 19800673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
    Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.